These procognitive effects are linked to many significant changes within the central nervous system, including enhanced neurogenesis and vasculogenesis. [5] [6] [7] A distinct advantage of GH is its approval profile and safety. Further, a recent retrospective combined registry analysis of published safety data from 1988 to 2016 on GH identified that there was no evidence to indicate that GH treatment increased mortality, stroke, or new malignancy. Background and Purpose-Cognitive impairment is a common outcome for stroke survivors. Growth hormone (GH) could represent a potential therapeutic option as this peptide hormone has been shown to improve cognition in various clinical conditions. In this study, we evaluated the effects of peripheral administration of GH at 48 hours poststroke for 28 days on cognitive function and the underlying mechanisms. Methods-Experimental stroke was induced by photothrombotic occlusion in young adult mice. We assessed the associative memory cognitive domain using mouse touchscreen platform for paired-associate learning task. We also evaluated neural tissue loss, neurotrophic factors, and markers of neuroplasticity and cerebrovascular remodeling using biochemical and histology analyses. Results-Our results show that GH-treated stroked mice made a significant improvement on the paired-associate learning task relative to non-GH-treated mice at the end of the study. Furthermore, we observed reduction of neural tissue loss in GH-treated stroked mice. We identified that GH treatment resulted in significantly higher levels of neurotrophic factors 
C ognitive impairment is a well-documented and problematic outcome for up to 80% stroke survivors. 1, 2 The cognitive domains that are commonly effected by stroke include memory, learning, and executive functions, which can lead to negative impacts on quality of life and the functional independence of individual stroke survivors. Currently, there are no recognized therapeutic options for cognitive impairment poststroke. If consideration is given to available options more broadly, a significant body of work suggests that growth hormone (GH) could represent a potential therapy. GH is a peptide hormone released from the pituitary gland. In addition to its classical actions on longitudinal body growth and intermediate metabolism, GH has been shown to improve cognition in both rodents and humans.
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Several studies have shown the beneficial effects of GH in promoting cognition in several experimental contexts including brain injury. 9, 10 Although modest in scope, GH has been examined for its ability to stimulate cognition poststroke. Pathipati et al, 11 , using an endothelin model of ischemia, examined the influence of GH delivered directly into the lateral ventricle of the brain starting 4 days poststroke for 42 days. Here, the authors identified the ability of GH to enhance aspects of spatial memory, using the Morris water maze. Specifically, they observed an improved performance in the probe trial with the GH-treated stroked animals spending more time in the platform zone than the non-GH-treated mice. Although promising, the results of Pathipati et al, 11 are limited in 2 significant ways. First, it is not clear whether peripheral GH delivery, as would be required clinically, could have the same procognitive benefits as when delivered intracerebroventricularly. Second, there is now broad consensus that classical tests of spatial working memory including the Morris water maze are subject to significant interpretational challenges and where possible newer assessments using more translationally relevant platforms, such as touchscreen testing are preferred. 12, 13 In this study, we evaluated the effects of peripheral administration of GH on cognitive function poststroke. Specifically, our primary hypothesis was that stroked mice treated with commercially available recombinant human GH (r-hGH) at 1.4 mg/kg body weight per day subcutaneously via mini-osmotic pumps for 28 days starting 48 hours poststroke would result in improved performance in cognition tasks relative to stroked non-GH-treated mice. Our secondary hypotheses were that r-hGH-treated stroked mice would show increased expression of neurotrophic factors, enhancement of neural plasticity and cerebrovascular remodeling, and reduced cerebral tissue loss.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. A detailed methods section is available in the online-only Data Supplement.
Ethical Statements
Animal research was undertaken in accordance to the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments). Experiments were approved by the University of Newcastle Animal Care and Ethics Committee (A-2014-432) and conducted in accordance with the New South Wales Animals Research Act and the Australian Code of Practice for the use of animals for scientific purposes.
Experimental Design
All the experimental groups are randomized, and all outcome analyses were performed by independent study team members blinded to the treatment condition. A total of 56 mice (C57BL/6, male, 8 weeks old) were used in this study. Details on animal numbers for each experiment and inclusion/exclusion criteria are included in Figure I in the online-only Data Supplement. The first cohort of mice was allocated for pilot study to investigate the bioactive effects of r-hGH in sham mice ( Figure IIA in the online-only Data Supplement). The second cohort of mice was used to investigate the effectiveness of r-hGH in facilitating cognitive recovery and the underlying mechanisms after experimental stroke ( Figure 1A ). Day 0, mice were subjected to photothrombotic occlusion or sham surgery. Day 2, mice received r-hGH or saline at 1.4 mg/kg body weight per day subcutaneously via mini-osmotic pumps for 28 days. To evaluate the effect of r-hGH on cognitive function, stroked mice received r-hGH or saline treatment were subjected to mouse touchscreen platform for paired-associate learning (PAL) task for 20 days (days 9-29 poststroke). Brains and blood samples were collected at 30 days poststroke.
Animal Surgery
Photothrombotic occlusion was performed as previously described. [14] [15] [16] [17] [18] Mini-osmotic pump (model 2004, Alzet) placement was performed as previously described.
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Assessment of Cognitive Deficits
The stroked mice were subjected to a mouse touchscreen platform for PAL task to assess the associative memory cognitive domain.
20,21
Biochemical Analysis
Protein homogenates from the peri-infarct samples were obtained as described. 17 The serum and peri-infarct supernatants were measured for IGF-1 (insulin-like growth factor-1) and VEGF (vascular endothelial growth factor) levels using commercially available mouse/rat IGF-1 Quantikine ELISA (MG100; R&D systems, MN) and mouse VEGF Quantikine ELISA (MMV00), respectively, according to the manufacturer's instruction. Western blotting was performed as previously described.
22
Histology Analysis
Cresyl violet staining was performed as described. 23 For immunoperoxidase labeling, free-floating sections were immunostained as described. 17 Images were acquired at ×20 using Aperio AT2 (Leica, Germany). ImageJ (1.50, National Institutes of Health) and Matlab (R2015a, MathWorks) were used to estimate tissue loss and to analyze intensity and area coverage of immunolabeling.
15-18
Sample Size Calculation
Sample size was estimated using the following formula:
Using preliminary data from PAL task (% correct rate; sham versus stroke), we obtained, SD=8.5 and an effect size of d=12. Allowing a type 1 error of 5%, α=0.05 with the power of 80%, and β=0.2, we calculated a sample size of 8 animals per group. More than 8 animals per group would ensure that a treatment effect will be detected, if present, with a >80% chance.
Statistical Analysis
All data were expressed as mean±SD and were analyzed using Prism for Windows Version 7.02, GraphPad Software. The primary outcome measurement was differences between Stroke+Saline and Stroke+r-hGH. Data from ELISA, PAL task (final session analysis) Western blotting, and immunoperoxidase labeling were analyzed using 2-tailed t test. Delta weight change, PAL task (20 sessions temporal analysis), tissue loss, and cumulative threshold were analyzed using 2-way ANOVA, followed by Sidak multiple comparisons. Pearson correlation was used to determine the association between serum neurotrophic factors and cognitive performance. A P value <0.05 was considered statistically significant.
Results
GH Treatment Increases Weight Gain and Serum Neurotrophic Factors
First, we confirmed in sham mice that the commercially available r-hGH has effects on mice physiology, when delivered subcutaneously via mini-osmotic pumps (sham+saline, n=6; sham+r-hGH, n=8; Figure II in the online-only Data Supplement). We measured the body weight weekly and presented the data as changes (delta, Δ) of body weight from baseline. The baseline body weight was 27.52±1.00 g (minimum=25.10 g; maximum=28.60 g). There was a significant interaction between the effect of time and r-hGH treatment on body weight (F (5, 60) =4.088; P=0.0029). We found a significant increase in serum IGF-1 (20.7%; P=0.0388) and VEGF (49.5%; P=0.0214) levels in r-hGH-treated mice compared with that in saline-treated mice. We also found a significant 17.8% decrease in blood glucose (P=0.0175) levels but no changes in the liver to body weight ratio.
Next, we investigated the effects of r-hGH treatment after permanent focal cerebral ischemia ( Figure 1 ). The baseline body weight was 26.95±1.99 g (minimum=23.40 g; maximum=31.10 g). There was a significant interaction between the effect of time and r-hGH treatment on body weight (F (5, 75) =7.435; P<0.0001). Post hoc analysis indicated a significant increase in body weight between 3 and 4 weeks after r-hGH treatment poststroke. We found a significant increase in serum IGF-1 (54.2%; P<0.0001) and VEGF (21.3%; P=0.0072) levels in stroked mice treated with r-hGH. There Figure 1 . The effects of recombinant human growth factor (r-hGH) treatment poststroke on physiological parameters. A, Experimental design. All mice received a focal photothrombotic stroke. Fourty-eight hours poststroke, mice were randomly treated with either saline or r-hGH via mini-osmotic pumps subcutaneously for 28 days, which were randomly distributed for either measurement of changes in body weight or assessment of cognitive function. B, r-hGH treatment poststroke significantly increased the body weight poststroke. Mice were euthanized 30 days poststroke. C, r-hGH treatment poststroke significantly increased serum IGF-1 (insulin-like growth factor-1) and VEGF (vascular endothelial growth factor) levels. Mean±SD. *P<0.05, **P<0.01, and ***P<0.001. PAL indicates paired-associate learning.
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was no significant change in blood glucose levels and liver to body weight ratio.
GH Treatment Improves Poststroke Cognitive Impairment and Reduces Tissue Loss
Mice were treated with saline (n=11) or r-hGH (n=9) 48 hours poststroke, followed by 7 days recovery. Then, mice were assessed using mouse touchscreen platform for PAL task for 20 consecutive days. We found a significant 22.4% increase in percentage correct rate (P=0.0092) in r-hGH-treated stroked mice compared with saline at final PAL session ( Figure 2A) . A range of metrics from the PAL task were also collected for temporal analysis. The data were presented as 4 blocks of mean of 5 consecutive sessions ( Figure III in the online-only Data Supplement). There was a significant effect of r-hGH treatment (F (1, 18) =5.606; P=0.0293) and time (F (3, 54) =17.83; P<0.0001) on percentage correct rate. Post hoc analysis indicated a significant 18% increase in percentage correct at fourth block after r-hGH treatment poststroke (P=0.0292). There was no significant effect in number of trials completed within 60 minutes, time to complete 36 trials, repeated tasks per trials, correct trials completed, and correct touch latency between stroked mice treated with r-hGH compared with saline.
Rostral caudal analysis of tissue loss revealed a significant effect of r-hGH treatment (F (1, 50) =5.601; P=0.0219) and at bregma levels (F (4, 50) =5.601; P=0.0219). Post hoc analysis indicated a significant 56.8% decrease in tissue loss at Bregma 0.0 after r-hGH treatment poststroke (P=0.0094; Figure 2B ).
GH Treatment Promotes IGF-1 and VEGF Levels Within the Peri-Infarct
The protein homogenates from the peri-infarct region of stroke+saline (n=8) and stroke+r-hGH (n=9) were analyzed along with sham+saline (n=6) using Western blotting. IGF-1 and VEGF (and other protein markers discussed in below sections) were normalized to β-actin and were expressed as a fold change of mean±SD for each group relative to the mean of the sham+saline group. We found a significant increase Figure 3 . Protein homogenates for the peri-infarct were analyzed biochemically for neurotrophic factors. A, IGF-1 (insulin-like growth factor-1) and (B) VEGF (vascular endothelial growth factor) levels were expressed as a fold change of mean±SD for each group relative to the mean of the sham+saline group (dotted line). Representative blots for IGF-1 and VEGF. Loading controls were performed by analysis of β-actin. We found a significant increase in IGF-1 and VEGF levels within the peri-infarct in stroked mice treated with recombinant human growth factor (r-hGH) compared with saline. ELISA further confirmed that r-hGH treatment poststroke significantly increased (C) IGF-1 and (D) VEGF levels within the peri-infarct region. Mean±SD. *P<0.05, **P<0.01, and ***P<0.001.
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in IGF-1 (43.6%; P=0.0054; Figure 3A ) and VEGF (23.8%; P<0.001; Figure 3B ) levels within the peri-infarct in stroked mice treated with r-hGH compared with saline. We further confirmed using ELISA that r-hGH treatment poststroke significantly increased IGF-1 (95.2%; P=0.0070; Figure 3C ) and VEGF (77.8%; P=0.0115; Figure 3D ) levels within the peri-infarct.
GH Treatment Promotes the Expression of Presynaptic and Myelin Markers Within the Peri-Infarct
We Figure 4A ). r-hGH treatment poststroke significantly increased SYN-1 (10.1%; P=0.0354) and MBP (45.4%; P=0.0414) levels ( Figure 4B ). We further confirmed the protein data using immunohistochemistry staining. Optical density of SYN-1 and MBP (and other staining discussed in below sections) within the peri-infarct was assessed using threshold analysis. In the periinfarct region, we found a significant increase in material thresholded for SYN-1 (757.1%; P=0.0032, at pixel intensity 150; Figure 5A ) and MBP (33.6%; P=0.0386, at pixel intensity 110; Figure 5B ) in stroked mice treated with r-hGH compared with saline. Sections were also counterstained with Cresyl violet for qualitative observation. For cumulative threshold analysis, see Figure IV in the online-only Data Supplement.
GH Treatment Promotes the Expression of Vascular Markers CD31 and Collagen-IV
We also analyzed the protein homogenates for markers of vasculature (CD31 and collagen-IV) using Western blotting. r-hGH treatment poststroke significantly increased expression levels of CD31 (56.8%; P=0.0033) but not collagen-IV (P=0.1240; Figure 6A ).
To assess the distribution and density of vasculature, we performed vessel digital reconstruction and threshold analysis on CD31 ( Figure 6B ) and collagen-IV ( Figure 6C 
Serum IGF-1 Positively Correlates With Cognitive Performance Poststroke
Pearson correlation analysis shows a significant positive correlation between serum IGF-1 levels and cognitive performance poststroke, as indexed by percentage correct rate at final PAL session (r=0.5914; P (Y=0.04493X+44.24) =0.0076). There was no significant correlation between serum VEGF levels and cognitive performance poststroke (r=0.398; P (Y=0.2271*X+46.01) =0.0915).
Discussion
In this study, we have shown that r-hGH delivered subcutaneously over a 28-day window starting 48 hours poststroke significantly improved performance in the PAL task, when compared with non-GH-treated stroked mice. We also provided support for our secondary hypotheses, including the ability of r-hGH to reduce loss of neural tissue, enhance expression of neurotrophic factors (IGF-1 and VEGF), and several markers of neural plasticity and vascular remodeling. We placed a particular focus on translational therapeutic considerations, most notably the route of GH administration and mode of cognitive testing. Collectively, these positive results from our study reinforce the concept of using GH as a potential treatment for promoting cognition poststroke.
Clinically, cognitive impairment is a significant concern for stroke survivors, and much effort has been directed toward the development of therapeutic strategies for preventing cognitive decline after stroke. The evidence supporting the potential use of GH as a safe and effective agent to promote cognitive function has continued to build over recent years. Already, promising small clinical studies have identified the therapeutic use of GH in patients who have experienced traumatic brain injury or stroke. [24] [25] [26] [27] [28] In the current study, we were motivated to extend the existing preclinical literature that has considered the potential procognitive effects of GH after stroke. 11 We used the photothrombotic stroke model, useful for its ability to produce highly consistent and repeatable ischemic injury. 29 Importantly, the photothrombotic stroke model has been reported to consistently elicit learning and memory deficits. 30, 31 To assess these deficits, we turned to touchscreenbased assessments as these are recognized to avoid many of 
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the limitations associated with classical assessments. 12 For instance, Morris water maze requires animal to swim to a hidden platform that is located beneath the surface of the water, which could be perceived as stressful situation. Chronic stress can have a significant impact on brain recovery and functional outcomes poststroke. 15, 17, 32 Clinically, stroke is associated with poorer performance in multiple cognitive domains, including associative memory. 33 Specifically, we used the PAL task that has been extensively studied in clinical assessment of cognition, 34 and the task available for rodents is analogous to clinical research. 35 Beyond this clinical translation aspect, PAL task is recognized to assess associative memory domain. With respect to our results, we compared the number of correct trials performed by GH-and non-GH-treated mice poststroke at the final session. This comparison indicated that GH-treated stroked mice made a significant 22.4% more correct choices on the PAL task relative to non-GH-treated mice, thus confirming our primary hypothesis.
Extending from our observations of the procognitive effects of GH, we also examined the impact on the neurorestorative effects, such as neural plasticity and cerebrovascular remodeling. As expected, stroke reduced NeuN, a marker of mature neurons, SYN-1, a presynaptic marker, PSD-95, a postsynaptic marker, and MBP, a marker of myelination. In support of our secondary hypotheses, GH treatment in stroked mice resulted in significantly higher protein levels of SYN-1 and MBP within the peri-infarct in comparison to saline treatment. These results were confirmed using immunohistochemistry, which revealed GH treatment significantly increased density of SYN-1-positive terminals by ≈7.5-fold and a moderate 33.6% increase in MBP-positive structures within the motor and somatosensory cortices. The presence of synaptogenesis and remyelination poststroke after GH treatment is a critical finding, as neuroplasticity is believed to play a critical role in the stroke recovery.
The effect of GH treatment poststroke on cerebrovascular remodeling has not previously been investigated. In the current Figure 6 . Detection of vascular markers within the peri-infarct region. A, Representative blots for CD31 (endothelial cell adhesion molecule) and collagen-IV (structural component of basement membranes). Recombinant human growth factor (r-hGH) treatment poststroke significantly increased expression levels of CD31 but not collagen-IV. B, CD31 and (C) collagen-IV immunostaining (left), digital reconstruction of positive labeled cells (middle), and the material thresholded at specific pixel intensity (PI; right). r-hGH treatment poststroke significantly increased area covered by CD31 and collagen-IV-positive staining. There were also significant increases in thresholded staining of CD31 (at PI 130) and collagen-IV (at PI 190) levels in stroked mice treated with r-hGH compared with saline. Mean±SD. *P<0.05, **P<0.01, and ***P<0.001. study, we considered 2 major vasculature markers. First, CD31, a cell adhesion molecule secreted by endothelial cells and modulates cell adhesion, endothelial cell migration, and angiogenesis. Second, collagen-IV, a basal lamina protein secreted by endothelial cells. Stroked mice in comparison to shams showed no change in both CD31 and collagen-IV vasculature protein markers within the peri-infarct 30 days poststroke. Studies have shown that stroke induces significant reduction in cerebrovascular density within the peri-infarct at 1 day poststroke. Interestingly, spontaneous biological recovery occurs by gradual increase in revascularization over several weeks after the initial stroke. 36, 37 Angiogenic response is essential for ischemic brain repair and in poststroke brain may indicate a higher demand for vascular support in regions undergoing active tissue reorganization. Importantly, GH treatment in stroked mice increased the density and area coverage of both CD31 and collagen-IV-positive cells, suggesting the possibility of GH-induced revascularization beyond what occurs with spontaneous recovery. There were no significant changes in average diameter of vessels in GH treatment (data not shown), suggesting that the changes of density and area coverage observed was driven by an increase in the total number of vessels and increases in their length. It should be pointed out that the relative increase in area coverage for these vascular markers is ≈40%, and these are comparatively high figures, in terms of angiogenesis.
GH treatment resulted in several biological effects that are completely consistent with those reported previously in the literature. Notably, mice treated with GH gained a significant amount of weight across the treated window. We also identified that GH resulted in significantly higher circulating levels of IGF-1 and VEGF, both of which are known to be elevated after GH treatment. The enhancement of IGF-1 and VEGF apart from confirming the efficacy of GH treatment in this model is also of interest as higher circulatory levels of these growth factors straight after stroke correlates with better long-term outcome in patients. 38, 39 Our data suggested that higher circulatory levels of IGF-1 is associated with better cognition in stroked mice. We also found a robust increase in IGF-1 and VEGF levels within the peri-infarct region of the brain in GH-treated stroked mice. One potential concern with GH treatment is its ability to promote diabetogenic effects. In the current study, we observed no stimulatory effects on glucose between GHand non-GH-treated mice, which we think is of potential clinical importance.
One observation from the current study that requires consideration is that stroked mice treated with GH exhibited significantly less tissue loss from the ipsilateral hemisphere. Although we cannot definitely account for these tissue gains, we would not be inclined to attribute them to GH-promoting neuronal survival within the infarct, as treatment of GH commenced at 48 hours poststroke at a time when most, if not all, neurons within the infarcted territory would have died. Instead, we would speculate that the greater tissue volume seen in GH-treated mice could be attributable to an increase in synaptogenesis, myelination, and vessel growth occurring within the ipsilateral hemisphere. However, we would also give consideration to glia, including astrocytes and microglia, as there is some evidence that these cells have significantly greater oxidative tolerance when compared with neurons. 40, 41 It will be of considerable interest to examine in future studies, using an approach such as bromodeoxyuridine tagging, 42 to specifically identify which populations are most responsible for the less severe levels of tissue loss observed in mice treated with GH and to determine the time frame in which this occurs.
There are multiple avenues to consider in terms of advancing the findings of the current study. First, with respect to the effects of GH on cognition, we note that we have only examined the associative memory cognitive domain. We were largely constrained to one assessment because of the significant time required to perform testing. Nevertheless, it would certainly be worthwhile for future studies to consider examining long-term memory and attention. Further dosing and timing studies on the procognitive effects of GH, such as how long after the cessation of the treatment do the cognitive enhancements persist for and specifically address whether a one-off or repeated administration would be required to promote cognition, are warranted.
Conclusions
We have shown that peripheral GH treatment poststroke stimulates cognitive recovery, which could make GH a useful therapeutic tool in the recovery phase of patients after stroke. Our findings of increased expression of neurotrophic factors, such as IGF-1 and VEGF, markers of synaptogenesis and myelination, and the formation of cerebrovascular networks confirm that GH has a wide range of neurorestorative effects that could have a potential in a clinical setting. Encouragingly, some small and pilot studies in humans indicate a positive outcome when GH treatment is used together with specific rehabilitation after traumatic brain injury or stroke. [24] [25] [26] [27] [28] The results from this study, supported by previous studies, suggest a rational for clinical intervention studies with GH after stroke.
